251300-30-8

Basic information

• Product Name: 5-Bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde
• Synonyms: 5-Bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde;5-Bromo-3-(trifluoromethyl)salicylaldehyde;5-Bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde 99%;5-Bromo-3-(trifluoromethyl)salicylaldehyde, 5-Bromo-3-formyl-2-hydroxybenzotrifluoride;5-Bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde99%
• CAS NO: 251300-30-8
• Molecular Formula: C₈H₄BrF₃O₂
• Molecular Weight: 269.0153696
• Mol File: 251300-30-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-Bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde(251300-30-8)
• EPA Substance Registry System: 5-Bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde(251300-30-8)

Safety Data

• Hazardous Substances Data: 251300-30-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-Bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde is utilized as a key intermediate in organic synthesis for the production of various complex organic compounds. Its presence of reactive functional groups facilitates multiple synthetic pathways, making it a versatile component in the construction of diverse molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-Bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde is employed as a building block for the development of new drugs. Its unique structure contributes to the design of molecules with potential therapeutic properties, aiding in the advancement of medicinal chemistry.
Used in Material Science:
5-Bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde may be used as a component in the development of new materials with specific properties. Its molecular structure can influence the physical and chemical characteristics of the materials, making it a candidate for applications in various material science fields.
Used in Agrochemicals:
5-Bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde also has potential applications in agrochemicals, where it could be used as a precursor for the synthesis of active ingredients in pesticides or other agricultural chemicals. Its unique structure may contribute to the development of more effective and targeted agrochemical products.

Upstream product

• 50824-04-9 4-bromo-2-(trifluoromethyl)phenol 
• 100-97-0 hexamethylenetetramine 
• 444-30-4 2-(trifluoromethyl)phenol 
• 336628-67-2 2-hydroxy-3-(trifluoromethyl)benzaldehyde 
• 336628-65-0 2-(methoxymethoxy)-1-(trifluoromethyl)benzene 
• 336628-66-1 2-(methoxymethoxy)-3-(trifluoromethyl)benzaldehyde 

Downstream Products

• 1285572-57-7 3-(3-cyano-4-hydroxy-5-trifluoromethylbenzoyl)-1,1-dioxo-1,2-dihydro-3H-1,3-benzothiazole 
• 1285573-58-1 5-bromo-1-diethoxymethyl-2-methoxy-3-trifluoromethylbenzene 
• 1285573-63-8 3-formyl-4-methoxy-5-trifluoromethylbenzoic acid 
• 1285573-65-0 5-cyano-4-methoxy-3-trifluoromethylbenzoic acid 
• 1285573-68-3 3-cyano-4-methoxy-5-trifluoromethylbenzoyl chloride 
• 1285573-71-8 3-(3-cyano-4-methoxy-5-trifluoromethylbenzoyl)-2,3-dihydro-1,3-benzothiazole 
• 1285573-75-2 3-(3-cyano-4-methoxy-5-trifluoromethylbenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 
• 1285572-59-9 3-(3-cyano-4-hydroxy-5-trifluoromethylbenzoyl)-1,2-dihydro-3H-1,3-benzothiazole 
• 1285572-60-2 3-(3-cyano-4-hydroxy-5-trifluoromethylbenzoyl)-1-oxo-2,3-dihydro-1,3-benzothiazole 
• 1285573-78-5 3-(3-cyano-4-methoxy-5-trifluoromethylbenzoyl)-1-oxo-2,3-dihydro-1,3-benzothiazole 
• 1285573-05-8 3-(3-dimethylcarbamoyl-4-hydroxy-5-trifluoromethylbenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 
• 1285575-54-3 methyl 3-formyl-4-methoxy-5-trifluoromethyl benzoate 
• 1360620-64-9 4-methoxy-5-trifluoromethylisophthalic acid-1-methyl ester 
• 1285575-58-7 methyl 3-dimethylcarbamoyl-4-methoxy-5-trifluoromethyl benzoate 

Relevant articles and documents

ORAL COMPLEMENT FACTOR D INHIBITORS

Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

As the NS4B inhibitor benzofuran analogs (by machine translation)

The present invention discloses a kind of as NS4B benzofuran analogue inhibitors, in particular to the formula (I) below or a pharmaceutically acceptable salt thereof. (by machine translation)

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF

The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula (A) : or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (A), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

Hepatitis C replication inhibitors that target the viral NS4B protein

We describe the preclinical development and in vivo efficacy of a novel chemical series that inhibits hepatitis C virus replication via direct interaction with the viral nonstructural protein 4B (NS4B). Significant potency improvements were realized through isosteric modifications to our initial lead 1a. The temptation to improve antiviral activity while compromising physicochemical properties was tempered by the judicial use of ligand efficiency indices during lead optimization. In this manner, compound 1a was transformed into (+)-28a which possessed an improved antiviral profile with no increase in molecular weight and only a modest elevation in lipophilicity. Additionally, we employed a chimeric "humanized" mouse model of HCV infection to demonstrate for the first time that a small molecule with high in vitro affinity for NS4B can inhibit viral replication in vivo. This successful proof-of-concept study suggests that drugs targeting NS4B may represent a viable treatment option for curing HCV infection.

NOVEL PHENOL DERIVATIVE

Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in FIG. 1; a pharmaceutically acceptable salt t

An improved method for the synthesis of 3-fluorosalicylic acid with application to the synthesis of 3-(Trifluoromethyl)salicylic acid

An improved method for the synthesis of 3-fluorosalicylic acid is described. A positional protective group strategy allows formylation selectively at the ortho position of 4-bromo-2-fluorophenol. Oxidation of the resulting salicylaldehyde to the salicylic acid, followed by debromination, affords 3-fluorosalicylic acid. The method has also been applied to the synthesis of 3-(trifluoromethyl)salicylic acid.